Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIRâ"¢ and ADAPTIR-FLEXâ"¢ platform technologies, today announced executive leadership transitions to support the Company's continued execution, drive achievement of l ...